High-dose therapy and hematopoietic stem and progenitor cell (HSPC) transplantation have dramatically improved survival in a wide range of malignancies. 1 Treatment is contingent upon mobilization of adequate numbers of HSPC. Mobilization failure affects 5% of normal healthy donors, 20-30% of all cancer patients and more than 60% of fludarabine-exposed patients.
1,2 Therefore, strategies to improve HSPC mobilization are necessary.
Proteases derived from neutrophils are central to the mechanism of granulocyte-colony-stimulating factor (G-CSF) mobilization of HSPC. Preclinical data demonstrate G-CSF-induced protease-dependent cleavage of the intercellular adhesive interactions which 'home' HSPC to the bone marrow (BM). 3 We have demonstrated that the granulocyte-differentiating properties of two retinoids-VTP195183 (a novel highly specific retinoic acid receptor alpha (RARa) agonist) and all trans-retinoic acid (ATRA, a pan-RAR agonist)-can be exploited in mobilization. These agents synergized with G-CSF to enhance peripheral blood (PB) HSPC content in both a 'poor mobilizer' and 'good mobilizer' murine model. 4 We sought to determine whether these findings would translate into the human setting; however, there are limited safety data on combining retinoids with G-CSF in humans.
There may be apprehension among clinicians owing to the theoretical risk of the retinoic acid syndrome (fever, leukocytosis, pleural and pericardial effusions, edema and multi-organ failure 5 ) when a RARa agonist is combined with a second potent stimulus for granulocyte differentiation (G-CSF), even in the absence of acute promyelocytic leukemia (APL). ATRA is approved for systemic therapy in humans and has a well-documented safety profile. We therefore designed an initial phase I clinical trial to test the safety of combining ATRA and G-CSF in patients with multiple myeloma and cutaneous lymphoma. Although primarily a phase I safety/toxicity trial, measurement of the kinetics of CD34 þ cell mobilization was a secondary end point. Using a dosing regimen schedule derived from murine experiments, 4 six patients (four females and two males) with multiple myeloma (n ¼ 4, all stage 3) or cutaneous lymphoma (n ¼ 2, one stage IVa, one stage Ib) received ATRA at 45 mg/m 2 /day p.o. for 7 days, followed by ATRA plus G-CSF (10 mg/kg/day, s.c.) for a further 7 days. PB CD34 þ cell counts and toxicity assessments were performed twice weekly for the first week, then daily during G-CSF treatment. Study drugs, clinical evaluations and blood safety monitoring continued until the CD34 þ cell count decreased to 5 Â 10 6 /l or below baseline. Toxicity data (NCI-CTC version 2.0) were collected for the 2 weeks of study drug treatment and a further 2 weeks of follow-up. The study was approved by the Peter MacCallum Cancer Centre Ethics committee and all patients provided signed consent.
All patients completed the 7 days of ATRA treatment, and 5/6 completed ATRA plus G-CSF treatment until the prescribed end points. Patient 6 ceased study drugs 1 day early owing to an unrelated intercurrent episode of sepsis (grade 3), which compromised further CD34 þ cell monitoring. The treatment was otherwise well tolerated, with no dose-limiting toxicities reported.
A mild (pgrade 2) elevated alkaline phosphatase (ALP) occurred in all six patients-an effect previously noted in studies of both drugs, independently. The ALP rise is probably osteogenic, as G-CSF is known to cause bone remodeling and a rise in the bone isoenzyme of ALP. 6 However, the leukocyte effects of both drugs could also contribute a proportion of leukocyte-derived ALP. Other adverse events were self-limited, including hypertriglyceridemia (n ¼ 5; grade 2 in one patient and grade 1 in four patients) and angular stomatitis (n ¼ 5; grade 3 in one patient), both well-recognized retinoid side effects. 7 Five patients experienced bone pain; an expected side effect due to G-CSF-induced myeloid hyperplasia; grade 3 in one patient. Also noted were elevated g-glutamyl transferase (n ¼ 3; grade 3 in one patient), injection site reaction (n ¼ 3; pgrade 2), headache (n ¼ 2; pgrade 2), peripheral edema (n ¼ 2; pgrade 2), thrombocytopenia (n ¼ 2; pgrade 2, pre-existing in one) and neuropathic pain (n ¼ 2; pgrade 2, pre-existing in both). Dry skin, elevated alanine aminotransferase, coryzal symptoms, diarrhea, nausea, lethargy and anxiety occurred in one patient each. Anorexia, anemia and renal impairment occurred in one patient each, but were pre-existing at the time of baseline investigations in each case.
Importantly, there was no evidence of the retinoid syndrome in this study. The occurrence of this syndrome in APL has been attributed variously to ATRA-induced changes in leukocyte activation and adherence, cytokine expression or alteration in deformability of malignant promyelocytes undergoing forced differentiation. 8, 9 In patients with APL, retinoid syndrome occurs mainly but not exclusively in those experiencing high initial white cell counts or leukocytosis (WBC 475 Â 10 was therefore required to avoid excessive leukocytosis, and no features of the retinoid syndrome were observed.
The fall in platelets in this study, although clinically nonsignificant, is biologically interesting (Figure 1) . Mild thrombocytopenia during G-CSF mobilization has been attributed to the leukapheresis process. Studies in nonleukapheresed patients have also noted thrombocytopenia with G-CSF mobilization, associated with sub-clinical splenic enlargement and therefore attributed to splenic sequestration in one study. 10 Others have proposed a platelet consumption effect secondary to G-CSF, with preserved or increased BM megakaryocytes, higher mean platelet volume and increased levels of platelet factor IV noted. 6 ATRA itself has not been directly associated with thrombocytopenia.
As a secondary end point in this study, PB CD34 þ cell kinetics showed definite mobilization in all patients, including three 'poor mobilizers' (patients 2, 3 and 6 in Figure 2) , with CD34 þ counts increasing above 5 Â 10 6 /l at a mean of 2 days (range 0-3 days) after G-CSF, and remaining elevated above this level for a mean of 5.3 (3-8 þ ) days (Figure 2) . Similar results were reflected in the PB colony-forming units granulocyte macrophage (CFU-GM) and burst-forming units (BFU) levels (results not presented).
The addition of ATRA to G-CSF in this study presented a possible outcome where ATRA may induce differentiation and commitment of primitive hematopoietic stem cells, with a theoretical adverse effect on both mobilization and engraftment. Although HSPC collection, transplantation and engraftment were not the end points in this purely þ cell kinetics during all trans-retinoic acid (ATRA) and ATRA plus granulocyte-colony-stimulating factor (G-CSF) (shaded) treatment.
observational study, it was reassuring to note that no such deleterious effect on CD34 þ cell mobilization was observed. Furthermore, in our own preclinical studies, G-CSF plus ATRA or VTP195183 mobilization in mouse models neither induced stem cell differentiation nor adverse effects on long-term engraftment of mobilized HSPC; indeed, VTP195183/G-CSF-mobilized cells showed superior early and equivalent late engraftment to cells mobilized with G-CSF alone, and neither ATRA nor VTP195183 pretreatment for 7 days adversely affected in vivo BM content of Lineage neg Sca-1 þ c-kit þ cells. 4 In conclusion, this study indicates that ATRA can be safely combined with G-CSF in patients with multiple myeloma and indolent lymphoma. The secondary end point of mobilization of CD34 þ cells was observed, including mobilization of CFU-GM and BFU-E. The ability of the highly specific RARa agonist VTP195183 combined with G-CSF to mobilize PB stem cells is therefore currently being evaluated in a randomized trial at our center.
